Shopping Cart
Remove All
Your shopping cart is currently empty
Lexatumumab (Synonyms: HGS-ETR 2, ETR2-ST01, DR5 mAB)
Catalog No. T76815 Copy Product Info
🥰Excellent
Lexatumumab (GHS-ETR 2) is a human excitatory monoclonal antibody targeting TRAIL receptor 2 that has anticancer activity and induces apoptosis in malignant mesothelioma. Lexatumumab can be used to study malignant pleural mesothelioma (MPM).
Lexatumumab
Copy Product Info🥰Excellent
Catalog No. T76815
Synonyms HGS-ETR 2, ETR2-ST01, DR5 mAB
Lexatumumab (GHS-ETR 2) is a human excitatory monoclonal antibody targeting TRAIL receptor 2 that has anticancer activity and induces apoptosis in malignant mesothelioma. Lexatumumab can be used to study malignant pleural mesothelioma (MPM).
Lexatumumab
Cas No. 845816-02-6
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $213 | In Stock | In Stock | |
| 5 mg | $645 | In Stock | In Stock | |
| 10 mg | $987 | - | In Stock | |
| 25 mg | $1,460 | - | In Stock | |
| 50 mg | $1,970 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:> 95%
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Lexatumumab (GHS-ETR 2) is a human excitatory monoclonal antibody targeting TRAIL receptor 2 that has anticancer activity and induces apoptosis in malignant mesothelioma. Lexatumumab can be used to study malignant pleural mesothelioma (MPM). |
| In vitro | Combining lexatumumab with cisplatin can synergistically inhibit cell growth and enhance apoptosis and death[1]. In different melanoma cell lines, lexatumumab (0-10 μg/ml, 72 h) induced varying degrees of cell death[2]. |
| In vivo | Lexatumumab ( 10mg / kg, intravenous injection, twice a week ) combined with Dacarbazine can increase the anti-tumor effect in mice [ 2 ]. |
| Synonyms | HGS-ETR 2, ETR2-ST01, DR5 mAB |
| Reactivity | Human |
| Verified Activity | Immobilized Human TNFRSF10B/TRAILR2/CD262 Protein at 2 μg/mL (30 μL/well) can bind Lexatumumab. The EC50 is 36.85 ng/mL.  |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | TNFRSF10B/TRAILR2/CD262 |
| Molecular Weight | 143.48 kDa |
| Cas No. | 845816-02-6 |
| Isotype | Human IgG1 lambda2 |
| Recommended Isotype Control |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Keywords
Preview
Related Tags: buy Lexatumumab | purchase Lexatumumab | Lexatumumab cost | order Lexatumumab | Lexatumumab in vivo | Lexatumumab in vitro | Lexatumumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.